Evoke Pharma’s stock skyrockets on impressive Gimoti data—what this means for diabetic gastroparesis patients
Shares in Evoke Pharma experienced an extraordinary 70% surge following the release of new, promising data on their flagship product, Gimoti. This growth marks a significant shift in the company’s stock performance, driven by recent findings showing that Gimoti, a unique metoclopramide nasal spray, provides meaningful benefits for diabetic gastroparesis patients, especially those using GLP-1 […]
